ArticleInternational journal of clinical oncology2026
Three-month follow-up of high-dose intravenous iron monotherapy for cancer-related anemia in an ESA-free oncology setting: a real-world cohort study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe extended our prior 1-month report to evaluate 3-month hemoglobin (Hb) outcomes, observed transfusion avoidance, and follow-up feasibility after high-dose intravenous iron monotherapy for cancer-related anemia in an erythropoiesis-stimulating agent (ESA)-free oncology setting.
methodsThis retrospective single-center cohort included adults with active solid malignancy who received high-dose intravenous ferric carboxymaltose or ferric derisomaltose monotherapy. Follow-up was evaluated at prespecified 1-month and 3-month windows. The primary analysis assessed Hb change from baseline to 3 months in evaluable non-transfused patients; observed transfusion avoidance was summarized descriptively.
resultsThe cohort comprised 65 patients. In-window Hb was available in 62 patients at 1 month and 42 at 3 months; 27 formed the non-transfused 3-month primary analysis set. Mean Hb increased from 9.01 ± 1.47 g/dL at baseline to 11.09 ± 1.67 g/dL at 3 months (mean change + 2.08 ± 1.72 g/dL; p < 0.001). Hb improvement was greater at 3 months than at 1 month, with a further paired increase among non-transfused patients (+ 0.52 ± 1.27 g/dL; p = 0.043). Observed transfusion avoidance was 81.5% at 1 month and 72.3% across available in-system follow-up within 3 months. Attrition was substantial: 23 patients were non-evaluable for 3-month Hb because of transfer/community follow-up (n = 15), death (n = 7), or data cutoff/window not reached (n = 1).
conclusionsIn this ESA-free oncology setting, high-dose intravenous iron monotherapy was associated with 3-month Hb improvement in selected evaluable non-transfused patients, with descriptively high observed transfusion avoidance and substantial attrition.
Indexed as
Identifiers
42400778What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.